"b cell receptors" trang 3 - tải miễn phí từ tailieuXANH
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
7    85    0
Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma
7    78    0
Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
9    110    0
Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation

Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation
13    62    0
Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts diseasefree and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression

Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts diseasefree and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression
11    59    0
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis
13    49    0
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: A single center experience

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: A single center experience
8    52    0
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients

The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients
8    63    0
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma

Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma
12    61    0
Prophylactic antibiotic treatment with TMPSMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy

Prophylactic antibiotic treatment with TMPSMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy
7    39    0
Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
7    55    0
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: A prospective, multicentre, non-interventional study

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: A prospective, multicentre, non-interventional study
10    64    0
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
7    67    0
Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
8    65    0
MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
11    78    0
DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation

DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation
10    66    0
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: Long-term results from a single center in China

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: Long-term results from a single center in China
11    56    0
Clinical characteristics and prognostic factors of bone lymphomas: Focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas

Clinical characteristics and prognostic factors of bone lymphomas: Focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas
9    59    0
Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas
10    51    0
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis
11    55    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.